Drug Profile
Ropsacitinib
Alternative Names: PF-06826647Latest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Priovant Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Cyclobutanes; Nitriles; Pyrazines; Pyrazoles; Skin disorder therapies; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Immunological disorders
- Discontinued Hidradenitis suppurativa; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis; Unspecified